Highest-materiality recent filing
Benitec Q3 net loss $0.24/shr, cash $184.8M; BB-301 clinical progress continues
Net loss $11.9M ($0.24/shr) vs $14.5M ($0.38/shr) in prior year quarter; total expenses $13.6M.
Benitec Q2 FY2026 net loss $11.8M; all Cohort 1 patients respond to BB-301 at 12 months
Net loss of $11.8M ($0.26 per share) vs $9.6M YoY; total expenses $13.4M (up from $10.8M).
Benitec Q1 net loss $9.0M; BB-301 100% responder rate; FDA Fast Track; raised $100M
Net loss of $9.0M ($0.22/sh) vs $5.1M ($0.18) YoY; total expenses $9.8M, up from $5.8M.
Benitec Biopharma prices $100M equity offering at $13.50/share (7.4M shares total)
Underwritten public offering of 5,930,000 shares plus 889,500-share underwriter option; concurrent registered direct offering of 1,481,481 shares to Suvretta Capital affiliates.
Benitec gets FDA Fast Track for BB-301 in OPMD; 100% response rate in Cohort 1
FDA granted Fast Track Designation to BB-301 for OPMD with dysphagia; BB-301 also has Orphan Drug Designation from FDA and EMA.
Benitec Biopharma FY2025 net loss $37.9M ($1.05/sh); BB-301 DSMB clears Cohort 2 enrollment
Net loss $37.9M ($1.05/share) vs $22.4M ($1.22/share) in FY2024; total expenses $41.8M (up 86%).
Benitec restates Q2 and Q3 FY2025 financials for stock-comp understatement; prior filings unreliable
Audit Committee concluded Dec 31, 2024 and Mar 31, 2025 unaudited financials should no longer be relied upon.
Benitec Biopharma reports DSMB recommends continuation of BB-301 Phase 1b/2a study after Cohort 1
Sixth and final subject of Cohort 1 safely treated with low dose of BB-301 in April 2025.
Benitec Biopharma closes ~$30.5M equity offering; issues 2.043M shares and pre-funded warrants
Gross proceeds ~$30.5M from underwritten offering of 1.143M shares + 300K pre-funded warrants at $13.00/$12.999 per share.
Benitec Biopharma raises ~$30M in underwritten and direct common stock offering at $13/share
Underwritten offering of 1,143,000 shares and 300,000 pre-funded warrants at $13.00/$12.9999 per unit.
Benitec reports durable improvements in swallowing function with BB-301 in OPMD interim results
Three subjects treated with low-dose BB-301 showed significant, clinically meaningful improvements in swallowing function at 12 months (Subjects 1,2) and 3 months (Subject 3) post-treatment.
Subject 1: 41% reduction in total dysphagic symptom burden (SSQ) 12-months post-treatment; VFSS improvements across consistencies.
Net loss $7.4M ($0.33/sh) vs $6.8M ($2.64/sh) year ago; basic shares rose from 2.6M to 22.1M on warrant exercises.
Benitec reports Q1 FY2025 net loss $5.1M; positive clinical data for BB-301 in OPMD
Net loss $5.1M ($0.48/sh) vs $5.9M ($3.05/sh) prior year; cash $67.8M.
Subject 1 at Day 270: 35% SSQ Total Score reduction, 33% VFSS TPR reduction for thin liquids.
Benitec Biopharma enters ATM sales agreement for up to $75 million common stock offering
Up to $75M in common stock may be sold at-the-market through agent Leerink Partners.
Benitec Biopharma gets ~$21.1M from Suvretta warrant exercise; shares outstanding rise to 17.9M
Suvretta Capital waived 19.99% beneficial ownership limit on warrants; new cap set at 49.9%.
Benitec Biopharma FY2024 net loss $22.4M, cash $50.9M; BB-301 shows swallowing improvement
Net loss of $22.4M ($5.51 per share) for FY2024; cash and equivalents $50.9M as of June 30, 2024.
Benitec reports durable swallowing improvements at 180 days for first BB-301 subject in Phase 1b/2a
Post-dose Total Pharyngeal Residue meaningfully reduced at 180 days vs pre-dose average for Subject 1.
Benitec reports Q3 net loss $4.3M, positive OPMD data, $40M PIPE closed
Net loss of $4.3M ($1.64 EPS) vs $4.4M ($2.67 EPS) in Q3 2023; revenue $0.
Benitec Biopharma raises $40M in oversubscribed PIPE financing at $4.80/share
Gross proceeds of $40M from sale of 5,749,152 shares at $4.80 and pre-funded warrants for 2,584,239 shares at $4.7999.
Benitec reports positive interim clinical data for BB-301 in OPMD first subject at 90 days
First subject showed improvements in videofluoroscopic swallowing studies and Sydney Swallow Questionnaire at Day 90 vs. pre-dose baseline.
Benitec Q2 net loss $6.8M; first BB-301 subject cleared DSMB review – enrollment continues
Net loss of $6.8M ($2.64 per share) for quarter ended Dec 31, 2023 vs $5.4M ($3.34) a year ago.
Benitec dosed first subject in Phase 1b/2a trial of BB-301 for OPMD dysphagia
BB-301 is a gene therapy candidate using Silence and Replace ddRNAi platform for Oculopharyngeal Muscular Dystrophy (OPMD).
Benitec Biopharma regains Nasdaq compliance with $28.6M equity offering
Regained compliance with Nasdaq minimum stockholders' equity rule via $28.6M net proceeds from August 2023 offering.
Net loss $19.6M ($14.12/share) vs $18.2M ($37.88/share) prior year; cash $2.5M at June 30, 2023.
Offering included 875,949 common shares, 15.1M pre-funded warrants, 16.0M common warrants; net proceeds ~$28.3M.
Benitec Biopharma receives FDA IND clearance for BB-301 gene therapy for OPMD
FDA cleared IND for BB-301, a silence-and-replace gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD).
Benitec Q3 net loss $4.4M; 9 subjects enrolled in OPMD study; on track for BB-301 dosing in 2H2023
Net loss of $4.4M ($0.16/shr) in Q3 2023 vs $3.3M ($0.40/shr) in Q3 2022; cash $6.6M at Mar 31, 2023.
Benitec Biopharma gets Nasdaq extension to Sept 5, 2023 for bid price compliance
Nasdaq granted Benitec an additional 180-day period until Sept 5, 2023 to meet the $1.00 minimum bid price rule.
Benitec Biopharma Q2 net loss $5.4M; cash $10.5M; first OPMD patient enrolled
Net loss of $5.4M ($0.20/share) vs $4.8M ($0.59/share) in Q2 2022; revenue $14K.
On May 22, 2026, Megan Boston, the Company’s chief financial officer and secretary and a member of the Board since 2016, notified the Board of her decision to resign solely from the Board and rotated off the Board as part of the Company’s ongoing Board composition and governance review.
On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed David Friedman to serve as a director of the Board, effective as of such date.
On June 26, 2024, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed Kishan (“Kishen”) Mehta to serve as a director of the Board, effective as of June 26, 2024.
Max materiality 0.85 · Median 0.60 · Most common event other_material